Friday, January 21, 2022
More

    Latest Posts

    Study finds hydroxychloroquine delays disability for least treatable form of multiple sclerosis

    Credit: CC0 public domain

    A study from the University of Calgary found promising results for the generic drug hydroxychloroquine when used to treat the development of disorders in primary progressive multiple sclerosis (MS), the most difficult form of autoimmune disease. Found. MS affects approximately 90,000 Canadians, of whom approximately 15% have been diagnosed with primary progressive MS, which is one of the highest rates in the world.

    A research team at Cumming School of Medicine, led by Dr. Marcus Kok and Dr. Wee Young, has been discovered. Hydroxychloroquine An 18-month study involving participants from the MS Clinic in Calgary helped delay the exacerbation of disability.The study was published in Annual report of neurology..

    “In primary progressive MS, there is no suitable treatment to stop or reverse the progression of the disease. The disorder gradually worsens over time,” said Hotchkiss Brian, a clinician researcher in the Department of Clinical Neuroscience. Koch, a member of the Institute (HBI), said. ). “Dr. Yong’s research team, with which we work closely, has been screening a large number of generic drugs over the years, and the results with hydroxychloroquine show some promise. Our trial is preliminary. Successful and needs further research. I would like to share these results. It will help inspire the work, especially the large ones. Clinical trials, To the future. “

    An experimental study known as the single-arm phase II futile trial followed 35 individuals between November 2016 and June 2021. At the end of the exam, only eight participants got worse. Hydroxychloroquine was generally well tolerated.

    Hydroxychloroquine is a more commonly used antimalarial drug to control the symptoms of autoimmune disorders such as rheumatoid arthritis and lupus erythematosus. It is widely used in rheumatic diseases and was generally chosen because of its high tolerability.

    A UCalgary study found promising results for the generic drug hydroxychloroquine when used to reduce the exacerbation of the disorder of primary progressive aphasia (MS), the most difficult form of autoimmune disease. I did. MS affects about 90,000 Canadians. It is one of the highest rates in the world and accounts for about 15% of people diagnosed with primary progressive MS. Credit: Hotchkiss Brain Institute

    “Based on our laboratory studies of MS models, we predicted that hydroxychloroquine would reduce the disability of people living with MS. Calgary has a vibrant bench-to-bedside MS program. Yes, we are delighted to see the research from Dr. Koch’s exam, “says Yong, a professor of clinical neuroscience and a member of the HBI.

    The cause of MS remains unknown. It is a disease in which the body’s immune system attacks its own tissues, which is generally long-lasting and often affects the brain, spinal cord, and optic nerve of the eye. It can cause problems with eyesight, balance, and muscle control, but the effects vary depending on the person suffering from the disease.

    The activities of the MS Clinical Trials team are partially supported by charitable donations from donors such as the Westman Charitable Foundation and the Swartout family. This particular study was also funded by a grant from the MS Translational Clinical Trial Program at the Hotchkiss Brain Institute.

    Dr. Koch and his team have been studying the effects of hydroxychloroquine on primary progressive MS for several years, including the possibility of achieving even greater results as a treatment in combination with other generic drugs of choice. Research continues.


    The end of hydroxychloroquine as a treatment for COVID-19


    For more information:
    Marcus W. Koch et al, Hydroxychloroquine in Primary Progressive Multiple Sclerosis, Annual report of neurology (2021). DOI: 10.1002 / ana.26239

    Quote: According to a study, hydroxychloroquine was obtained from https: //medicalxpress.com/news/2022-01-hydroxychloroquine-disability-treatable-multiple-sclerosis.html on January 13, 2022 for multiple sclerosis. Delays the most difficult form of disability (January 13, 2022)

    This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.

    Study finds hydroxychloroquine delays disability for least treatable form of multiple sclerosis Source link Study finds hydroxychloroquine delays disability for least treatable form of multiple sclerosis

    The post Study finds hydroxychloroquine delays disability for least treatable form of multiple sclerosis appeared first on California News Times.

    Latest Posts

    Don't Miss

    Stay in touch

    To be updated with all the latest news, offers and special announcements.